🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "huge turning point" in the fight against superbug strains of the pathogen, according to researchers.

An International Health Concern

The sexually transmitted infection are on the rise globally, with estimates suggesting over 82 million instances annually. Especially elevated rates are seen in Africa and countries within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. In England, cases have hit a historical peak, while rates across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an important and timely step in the face of growing infection rates, the spread of superbugs and the very limited therapeutic options presently on offer.”

Public health authorities are increasingly worried about the increase in antibiotic-resistant strains. The World Health Organization has classified it as a "priority pathogen". A tracking program found that the effectiveness of key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Drugs Receive Authorization

One new antibiotic, marketed under the name a brand name, was cleared by the American regulatory agency in mid-December for combating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Scientists believe that specific application of this new drug will help hinder the development of resistance.

Gepotidacin, originating from the drugmaker GSK, was also approved in the same week. This drug, which is additionally indicated for urinary tract infections, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin emerged from a innovative non-profit model for antibiotic development. The non-profit organisation GARDP collaborated with the drug firm its industry partner to develop it.

“This milestone signifies a major breakthrough in the management of multidrug-resistant gonorrhoea, which up to this point has been outpacing medical innovation.”

Research Study Data and Worldwide Availability

Based on data detailed in a prominent scientific publication, zoliflodacin cured the vast majority of cases of the STI. This places it at an comparable level with the typical regimen, which uses a dual-drug approach. The study included hundreds of patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, GARDP has the authority to register and commercialise the drug in many low-income and middle-income countries.

Medical professionals directly involved have expressed optimism. Access to a one-pill regimen like this is seen as a "revolutionary step" for managing the epidemic. This is deemed crucial to alleviate the strain of the infection for individuals and to prevent the spread of untreatable gonorrhoea worldwide.